Key Takeaways from the RELATIVITY-047 Trial: Managing Advanced Melanoma
Panelists discuss how the RELATIVITY-047 trial data highlights the efficacy of nivolumab plus relatlimab in managing advanced melanoma, offering improved progression-free survival with a favorable safety profile compared to with nivolumab alone.
EP: 1.Treatment Decisions in Metastatic Melanoma: Immunotherapy vs Targeted Therapy
Now Viewing
EP: 2.Key Takeaways from the RELATIVITY-047 Trial: Managing Advanced Melanoma
EP: 3.Indirect Treatment Comparison: RELATIVITY-047 and CheckMate 067
EP: 4.Dual Immunotherapy IO Treatment and Sequencing Decisions for Melanoma
EP: 5.Insight on Treating Patients With Melanoma With Brain Metastases
EP: 6.Expert Insight on Using Dual-IO Regimens for Melanoma in Real-World Practice
EP: 7.Potential Roles for First-Line Targeted Therapy for Advanced Melanoma
EP: 8.Key Takeaways From ITC Analysis of First-Line Dual-IO Treatments in Advanced Melanoma
EP: 9.Nivolumab Combinations Show Best Treatment Options for Advanced Melanoma
Recent Videos
